Objective—To evaluate adverse effects and survival times in dogs with osteosarcoma that received a single SC infusion of carboplatin as adjunctive chemotherapeutic treatment following limb amputation or limb-sparing surgery.
Design—Retrospective case series.
Animals—17 client-owned dogs with spontaneously occurring osteosarcoma.
Procedures—Medical records of dogs that underwent limb amputation or limb-sparing surgery followed by a single continuous SC infusion of carboplatin (total dose, 300 mg/m2 infused over 3, 5, or 7 days) were evaluated. Signalment, tumor location, type of surgery (amputation or limb-sparing), duration of carboplatin infusion, results of hematologic and serum biochemical analyses, and adverse effects were recorded. Kaplan-Meier survival analysis was performed.
Results—Median survival time for all dogs was 365 days. Nine dogs had adverse bone marrow–related (hematologic) effects, 1 had adverse gastrointestinal effects, and 7 had infections at the surgical site. No significant differences were detected in survival times of dogs grouped according to tumor location, type of surgery, duration of carboplatin infusion, or development of postoperative infection.
Conclusions and Clinical Relevance—Median survival time and adverse effects in dogs with osteosarcoma that received a single SC infusion of carboplatin over a 3-, 5-, or 7-day period as adjunctive treatment following limb amputation or limb-sparing surgery were comparable to those of previously reported chemotherapy protocols requiring IV drug administration over several weeks. Further investigation is needed to evaluate the efficacy of this protocol as adjunctive treatment for osteosarcoma and other tumors in dogs.
Objective—To determine outcomes for dogs with soft tissue sarcomas in the distal aspects of the limbs that underwent second intention healing after wide excision (2-cm lateral surgical margins and a margin 1 fascial plane deep) of the tumors.
Design—Retrospective case series.
Animals—31 dogs with soft tissue sarcomas in the distal aspects of the limbs that underwent second intention healing following wide local excision of their tumors.
Procedures—Tumors were excised with 2-cm lateral margins and a margin 1 fascial plane deep to tumors. Wounds healed by means of second intention. Time to healing, complications during healing, and information regarding tumor recurrence were recorded.
Results—All tumors were excised with histologically tumor-free margins. Twenty-nine (93.5%) wounds healed completely by second intention (median time, 53 days). Two (6.5%) dogs required free skin graft procedures to facilitate healing. Complications during open wound management developed for 7 (22.6%) dogs. Long-term complications were detected for 8 (25.8%) dogs, including intermittent epidermal disruption (5/31 [16.1%]) and wound contracture (3/31 [9.7%]). All complications were managed conservatively. Local tumor recurrence was detected for 1 (3.2%) dog. Median follow-up time was 980 days (range, 380 to 2,356 days). No patients died because of tumor-related causes.
Conclusions and Clinical Relevance—Results of this study indicated second intention healing of large wounds in the distal aspects of the limbs was complete and typically without complications for dogs that underwent wide excision of soft tissue sarcomas. Wide local excision of soft tissue sarcomas in the distal aspects of the limbs with 2-cm lateral margins and margins 1 fascial plane deep to the tumors provided excellent long-term local tumor control.
Objective—To determine the signalment, tibial plateau leveling osteotomy (TPLO) plate type, clinical staging information, treatment, and oncological outcome in dogs that developed osteosarcoma at the proximal aspect of the tibia following TPLO and to calculate the interval between TPLO and osteosarcoma diagnosis.
Design—Multi-institutional retrospective case series.
Procedures—Medical records from 8 participating institutions were searched for dogs that developed osteosarcoma (confirmed through cytologic or histologic evaluation) at previous TPLO sites. Signalment, TPLO details, staging tests, treatment data, and outcome information were recorded. Descriptive statistics were calculated, and disease-free intervals and survival times were evaluated by means of Kaplan-Meier analysis.
Results—29 dogs met the inclusion criteria. The mean age was 9.2 years and mean weight was 45.1 kg (99.2 lb) at the time of osteosarcoma diagnosis. Most dogs had swelling over the proximal aspect of the tibia (17/21) and lameness of the affected limb (28/29). The mean interval between TPLO and osteosarcoma diagnosis was 5.3 years. One type of cast stainless steel TPLO plate was used in most (18) dogs; the remaining dogs had received plates of wrought stainless steel (n = 4) or unrecorded type (7). Twenty-three of 29 dogs underwent treatment for osteosarcoma. Median survival time for 10 dogs that underwent amputation of the affected limb and received ≥ 1 chemotherapeutic treatment was 313 days.
Conclusions and Clinical Relevance—Results supported that osteosarcoma should be a differential diagnosis for dogs with a history of TPLO that later develop lameness and swelling at the previous surgical site. Oncological outcome following amputation and chemotherapy appeared to be similar to outcomes previously reported for dogs with appendicular osteosarcoma.